TF
Therapeutic Areas
Daré Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DARE to PLAY™ (Sildenafil Cream) | Female Sexual Arousal Disorder | Approved |
| Ovaprene® | Hormone-Free Contraception | Phase 3 |
| DARE-HPV1 | Persistent High-Risk HPV Infection | Phase 2 |
| DARE to RESTORE™ (DARE-BV1) | Bacterial Vaginosis / Vaginal Microbiome | Phase 2b |
| DARE to RECLAIM™ (DARE-FRT1) | Vaginal Dryness (Menopause) | Phase 2 |
| DARE to PLAN™ (DARE-LAI1) | Long-Acting Injectable Contraception | Phase 1 |
| DARE to FIGHT™ (DARE-VVD1) | Recurrent Vulvovaginal Candidiasis | Preclinical |
| DARE to SUPPORT™ | Pregnancy Support | Not Disclosed |
Leadership Team at Daré Bioscience
SM
Sabrina Martucci Johnson
Founder, President, Chief Executive Officer & Director
JA
John A. Fair
Chief Business and Strategy Officer
DL
David L. Friend
Chief Development Officer
LW
Lisa Walters-Hoffert
Chief Financial Officer
GW
Gregory W. Matz
Senior Vice President, Pharmaceutical Development